

Development of STAT6 blocking therapeutic drug in systemic sclerosis with targeting profibrotic T cells and fibroblasts

Catholic University, Medical college, LaTIM(Lab of Translational ImmunoMedicine)



가톨릭대학교 산학협력단

IMMUNOLOGY	Hit
Product Type	PROTAC
Indication	Systemic Sclerosis
Target	STAT6
MoA(Mechanism of Action)	STAT6 protein degrader
Competitiveness	<ul style="list-style-type: none"> • Compared to small molecule drugs, PROTAC display multiple benefits that can be targeted specific molecules. • STAT6 is major transcription factor for expression of pro-fibrotic cytokines and fibroblast development. STAT6 significantly enhance fibrosis and inflammation in systemic scleroderma. • STAT6 PROTAC is a first-in-class candidate for systemic scleroderma that can inhibit fibroblast and pro-fibrotic T cell activity. • We aim to develop STAT6 PROTAC therapeutic drug for scleroderma with targeting profibrotic T cells and fibroblast.
Development Stage	Hit
Route of Administration	oral administration